Brief: Rocket Pharmaceuticals Announces European Medicines Agency Acceptance Of Rp-l102 Marketing Authorization Application For The Treatment Of Fanconi Anemia
02/04/2024 11:04
April 2 (Reuters) - Rocket Pharmaceuticals Inc RCKT.O :
* ROCKET PHARMACEUTICALS INC: BIOLOGICS LICENSE APPLICATION
FOR FA
REMAINS ON TRACK FOR SUBMISSION TO U.S. FDA IN FIRST HALF OF
2024
* ROCKET PHARMACEUTICALS ANNOUNCES EUROPEAN MEDICINES AGENCY
ACCEPTANCE OF RP-L102 MARKETING AUTHORIZATION APPLICATION FOR
THE TREATMENT OF FANCONI ANEMIA
Source text for Eikon: ID:nBw4y4lzma
Further company coverage: RCKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket Pharmaceuticals
See all newsRocket Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Rocket Pharmaceuticals posts Q2 profit helped by PRV sale
Brief: Rocket Pharmaceuticals Q2 EPS USD 1.08